- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00962390
Efficacy and Safety of S-Equol on Men With Benign Prostatic Hyperplasia
April 12, 2017 updated by: Ausio Pharmaceuticals, LLC
Randomized, Double Blind, Multicenter, Placebo Controlled, Proof of Concept Trial to Assess the Efficacy and Safety of 4 Weeks Treatment With AUS 131 (S Equol) on Benign Prostatic Hyperplasia
The purpose of this study is to assess the safety and effectiveness of S-equol in men with benign prostatic hyperplasia.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study is a phase 2a, randomized, double blind, multicenter, placebo controlled, parallel group, proof of concept study comparing the efficacy, safety, and acceptability of S-equol to placebo in patients with benign prostatic hyperplasia.
The study objective is to examine a dose response of 3 dose levels of S equol versus placebo on prostate specific antigen concentrations in patients with benign prostatic hyperplasia.
The safety of S-equol will be evaluated during the study.
Study Type
Interventional
Enrollment (Actual)
116
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Ahmedabad, India
- Samved Hospital
-
Bangalore, India
- St. John's Medical College Hospital
-
Bangalore, India
- M S Ramaiah Memorial Hospital
-
Delhi, India
- G S Medical College and KEM Hospital
-
Delhi, India
- Indraprastha Apollo Hospital
-
Delhi, India
- V M Medical College and Safdarjung Hospital
-
Jaipur, India
- SMS Hospital
-
Mangalore, India
- A J Hospital and Research Center
-
Pune, India
- Ruby Hall Clinic
-
Pune, India
- Inamdar Multispecialty Hospital
-
-
-
-
Alabama
-
Huntsville, Alabama, United States, 35801
- Medical Affiliated Research Center
-
-
Florida
-
Aventura, Florida, United States, 33180
- South Florida Medical Research
-
Clearwater, Florida, United States, 33761
- Tampa Bay Medical Research
-
-
Utah
-
West Jordon, Utah, United States, 84088
- Advanced Clinical Research
-
-
Virginia
-
Norfolk, Virginia, United States, 23507
- Clinical Research Associates of Tidewater
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
48 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Is male > 50 years of age at Screening.
- Has a normal digital rectal exam with the exception of prostate enlargement.
- Has suffered from symptoms of BPH for at least the 6 months before Screening.
- Has a prostate volume ≥ 20 mL and ≤ 70 mL as assessed by ultrasound.
- Has a serum PSA concentration > 1.5 ng/mL and ≤ 10 ng/mL at Screening.
- Has an IPSS > 13 at Screening and Baseline.
- Has a Qmax > 5 cc/sec and < 15 cc/sec with a voided volume ≥ 125 cc at Screening (and Baseline, if applicable).
Exclusion Criteria:
- Has a known history of allergic reaction or clinically significant intolerance to ingredients of the study drug.
- Neurogenic bladder dysfunction.
- Has bladder neck contracture or urethral stricture.
- Has acute or chronic prostatitis or urinary tract infection.
- Has, or has a history of, prostate cancer or carcinoma of the prostate suspected on digital rectal exam or transrectal ultrasound, or has a serum PSA concentration > 10 ng/mL; patients with a PSA concentration > 4 ng/mL and ≤ 10 ng/mL must have prostate cancer ruled out to the satisfaction of the investigator.
- Has a residual void volume > 250 mL.
- Has any clinically significant unstable condition that, in the opinion of the investigator, could compromise the patient's welfare, ability to communicate with the study staff, or otherwise contraindicate study participation.
- Shows presence of any manifest premalignant or malignant disease except treated skin cancers (except melanoma).
- Has a history of smoking more than 5 cigarettes daily within the year before Screening.
- Has resting systolic blood pressure (BP) > 160 mmHg or < 90 mmHg, or diastolic BP > 90 mmHg or < 60 mmHg at Screening.
- Has bladder stones as detected by ultrasound.
- Has hematuria of unknown etiology.
- Had previous prostate surgery or other invasive treatment for BPH.
- Had prior radiation to the pelvis.
- Has Parkinson's disease or multiple sclerosis.
- Had stroke or myocardial infarction within 5 months before Baseline.
- Has abnormal screening electrocardiogram (ECG) or unstable angina or severe congestive heart failure.
- Has active liver disease renal insufficiency with creatinine > 1.7 mg/dL, or clinically significant abnormal hemoglobin, white blood cell count, or platelet count.
- Has a history of postural hypotension or has a fall in systolic BP > 20 mm Hg after 2 minutes in a standing position.
- Received alpha blocker therapy within 28 days before Baseline.
- Received androgens, anti androgens, 5 alpha reductase inhibitors, or luteinizing hormone releasing hormone (LHRH) analogs within 3 months before Baseline.
- Received tricyclic antidepressants or plant extracts (e.g., saw palmetto) within 1 month before Baseline.
- Received sedating antihistamines, sympathomimetics, or anticholinergics within 1 week before Baseline.
- Has initiated new use (i.e., within the past 4 weeks before Screening) or otherwise are not on stable doses of phosphodiesterase 5 inhibitors during the 4 weeks before Screening.
- Has known or suspected history of alcoholism or drug abuse or misuse within the last 5 years.
- Is considered by the investigator, for any reason (including, but not limited to, the risks described as precautions, warnings, and contraindications in the current version of the Clinical Investigator's Brochure for AUS 131 [S equol]), to be an unsuitable candidate to receive the study drug.
- Has tested positive on the urine drug screen.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo
|
Experimental: 150mg S-equol
|
10mg S-equol 50mg S-equol, & 150mg S-equol
Other Names:
|
Experimental: 50mg S-equol
|
10mg S-equol 50mg S-equol, & 150mg S-equol
Other Names:
|
Experimental: 10 mg S-equol
|
10mg S-equol 50mg S-equol, & 150mg S-equol
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Baseline at Week 4 in Prostate Specific Antigen (PSA) Concentration.
Time Frame: 4 weeks
|
Prostate specific antigen is considered to be the most sensitive measure of S-equol effects on the prostate, due to the expected effects of S-equol on the androgen receptor axis.
In this proof-of-concept study, a population of 124 male subjects was estimated to achieve approximately 104 completed subjects (based on an estimated drop-out rate of 15%) to examine the dose-response compared to placebo.
A sample size of 26 subjects in each treatment arm was considered to be adequate to observe a trend in this proof-of-concept study.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Prostate Volume From Baseline at Week 4
Time Frame: 4 weeks
|
Prostate size as measured by prostate volume as assessed by transrectal ultrasound.
|
4 weeks
|
Change in Qmax From Baseline at Week 4
Time Frame: 4 weeks
|
4 weeks
|
|
Categorical Change in Qmax From Baseline at Week 4
Time Frame: 4 weeks
|
4 weeks
|
|
Percent Change in Qmax From Baseline at Week 4
Time Frame: 4 weeks
|
4 weeks
|
|
Change in Void Volume From Baseline at Week 4
Time Frame: 4 weeks
|
4 weeks
|
|
Change in Post-Void Residual Volume From Baseline at Week 4
Time Frame: 4 weeks
|
4 weeks
|
|
Change in in Dihydrotestosterone Concentration From Baseline at Week 4
Time Frame: 4 weeks
|
4 weeks
|
|
Change in Luteinizing Hormone Concentration From Baseline at Week 4
Time Frame: 4 weeks
|
4 weeks
|
|
Change in Total Testosterone Concentration From Baseline at Week 4
Time Frame: 4 weeks
|
4 weeks
|
|
Participants Assessment of Nocturia at Week 4
Time Frame: 4 weeks
|
Participants were asked to rate their change in nocturia (number of times you wake from sleep to urinate) since the Baseline Visit.
|
4 weeks
|
Investigators Assessment of Nocturia at Week 4
Time Frame: 4 weeks
|
Investigators were asked to rate participant's change in nocturia since the Baseline Visit.
|
4 weeks
|
Change in I-PSS Total Score From Baseline at Week 4
Time Frame: 4 weeks
|
The International Prostate Symptom Score (I-PSS) is based on the answers to seven questions concerning urinary symptoms and one question concerning quality of life.
Each question concerning urinary symptoms allows the patient to choose one out of 6 answers indicating increasing severity of the particular symptom.
The answers are assigned points from 0 to 5. The total score can therefore range from 0 to 35 (asymptomatic to very symptomatic).
The first seven questions of the I-PSS are identical to the questions appearing on the American Urological Association (AUA) Symptom Index which currently categorizes symptoms as follows: Mild (symptom score less than of equal to 7); Moderate (symptom score range 8-19); and Severe (symptom score range 20-35).
A reduction in I-PSS Total Score is consistent with improvement in symptoms of BPH.
|
4 weeks
|
Change in DAN Prostate Symptom Scale From Baseline at Week 4
Time Frame: 4 weeks
|
The questionnaire is made up of two kinds of questions: intensity of a symptom and bothersomeness of a symptom.
Prostate symptoms are addressed in questions 1 - 12 and sexual function in questions 13 - 15. Patients indicate how intense/frequent (scoring 0, 1, 2, or 3; where 0 represents the best case and 3 the worst case) and how bothersome the symptom (scoring 0, 1, 2, or 3; where 0 is 'not at all' and 3 is 'very much').
DAN-PSS total and DAN-PSS total sexual function score were calculated by multiplying the frequency score by the trouble score of each symptom, and then adding the resulting figures.
The possible values of DAN-PSS total ranged from 0 to 108 and of DAN-PSS total sexual function score ranged from 0 to 27.
A reduction in DAN-PSS total and/or sexual function score is consistent with improved BPH symptoms/sexual functioning.
|
4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Donald Bergner, MD, Tampa Bay Medical Research
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
January 1, 2016
Study Completion (Actual)
January 1, 2016
Study Registration Dates
First Submitted
August 19, 2009
First Submitted That Met QC Criteria
August 19, 2009
First Posted (Estimate)
August 20, 2009
Study Record Updates
Last Update Posted (Actual)
May 19, 2017
Last Update Submitted That Met QC Criteria
April 12, 2017
Last Verified
April 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- AUS CT04
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Benign Prostatic Hyperplasia
-
San Carlo di Nancy HospitalElesta S.R.L.CompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy | Benign Prostatic Hypertrophy With Outflow Obstruction | Prostate HyperplasiaItaly
-
St. Joseph's Healthcare HamiltonOntario Ministry of Health and Long Term CareCompletedBenign Prostatic HyperplasiaCanada
-
GlaxoSmithKlineCompletedBenign Prostatic Hyperplasia
-
Catholic University of the Sacred HeartCompletedBenign Prostatic Hyperplasia (BPH) | Benign Prostatic Enlargement (BPE)Italy
-
Boston Scientific CorporationCompletedProstatic Hyperplasia | Benign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic, Czechia, Sweden
-
Boston Scientific CorporationCompletedBenign Prostatic Hyperplasia | Prostatic Hyperplasia, Benign | Prostatic Hypertrophy | Prostatic Hypertrophy, Benign | Adenoma, Prostatic | Prostatic Adenoma | RezumDominican Republic
-
IMBiotechnologies Ltd.CompletedBenign Prostatic Hyperplasia | Benign Prostatic HypertrophyCanada
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Not yet recruitingLower Urinary Tract Symptoms | Benign Prostate Hyperplasia | Benign Prostatic Hypertrophy With Outflow Obstruction
-
IRCCS Policlinico S. MatteoCompletedBenign Prostatic Hyperplasia | Benign Prostatic Hypertrophy With Outflow ObstructionItaly
-
American Medical SystemsCompletedBenign Prostatic Hyperplasia | BPH | Benign Prostatic Hypertrophy | Prostate Disease
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States